Accéder au contenu
MilliporeSigma
Toutes les photos(1)

Principaux documents

T2005010

Triflusal impurity B

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

2-Hydroxy-4-(trifluoromethyl)benzoic acid, 4-(Trifluoromethyl)salicylic acid

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme

Sélectionner une taille de conditionnement

15 MG
169,00 $

169,00 $

Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Devis pour commande en gros
Toutes les photos(1)

Sélectionner une taille de conditionnement

Changer de vue
15 MG
169,00 $

About This Item

Formule empirique (notation de Hill) :
C8H5F3O3
Numéro CAS:
328-90-5
Poids moléculaire :
206.12
Code UNSPSC :
41116107
Nomenclature NACRES :
NA.24

169,00 $

Veuillez contacter notre Service Clients pour connaître la disponibilité de ce produit.
Devis pour commande en gros

Qualité

pharmaceutical primary standard

Famille d'API

triflusal

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

FC(F)(F)c1cc(c(cc1)C(=O)O)O

InChI

1S/C8H5F3O3/c9-8(10,11)4-1-2-5(7(13)14)6(12)3-4/h1-3,12H,(H,13,14)

Clé InChI

XMLFPUBZFSJWCN-UHFFFAOYSA-N

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Triflusal impurity B EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documents section.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

J A González-Correa et al.
Naunyn-Schmiedeberg's archives of pharmacology, 371(1), 81-88 (2004-12-17)
Triflusal is a fluorinated derivative of acetylsalicylic acid (ASA) with demonstrated antithrombotic activity. Recently, evidence for a neuroprotective effect has been obtained. The aim of this study was to compare the neuroprotective effects of the main metabolite of triflusal (2-hydroxy-4-trifluoromethylbenzoic
Anna Argemí et al.
Journal of pharmaceutical and biomedical analysis, 46(3), 456-462 (2007-12-21)
This study describes the development and evaluation of an analytical method for the characterization of triflusal (2-acetoxy-4-(trifluoromethyl) benzoic acid) dispersed in sustained delivery systems prepared using supercritical fluid impregnation technology. Characterization assays comprised the determination of the percentage of triflusal
R Mis et al.
European journal of clinical pharmacology, 42(2), 175-179 (1992-01-01)
2-hydroxy-4-trifluoromethylbenzoic acid (HTB) is the main active metabolite of the platelet antiaggregant drug triflusal. Its binding to plasma proteins of rats and healthy volunteers in vitro and in vivo has been studied. Rats were given a single oral dose of
J Ramis et al.
European journal of drug metabolism and pharmacokinetics, 16(4), 269-273 (1991-10-01)
The pharmacokinetic profile of triflusal (2-acetoxy-4-trifluoromethyl benzoic acid) and its main metabolite HTB (2-hydroxy-4-trifluoromethyl benzoic acid) has been studied in 8 healthy subjects (4 males and 4 females), after a single oral dose of 900 mg of triflusal. Plasma concentrations
J Ramis et al.
International journal of clinical pharmacology, therapy, and toxicology, 28(8), 344-349 (1990-08-01)
Triflusal pharmacokinetics were evaluated in 8 healthy subjects after a single 300 mg dose and after repeated doses of 300 mg every 8 h and 600 mg every 24 h during 13 days, with the aim of establishing a relationship
Afficher tous les articles scientifiques apparentés

Questions

Reviews

No rating value

Active Filters

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique